ATRA:NAS (USA) Also trade in: Germany

Atara Biotherapeutics Inc

$ 31.86 -0.72 (-2.21%)
Volume: 401,240 Avg Vol (1m): 432,983
Market Cap $: 1.47 Bil Enterprise Value $: 1.16 Bil
P/E (TTM): 0.00 P/B: 4.31
Earnings Power Value 3.72
Net Current Asset Value 5.86
Tangible Book 7.4
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 8/10

Current vs industry vs history
Cash-to-Debt No Debt
N/A
Interest Coverage No Debt
N/A
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 13.69
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC -807.15%
WACC 22.97%

Profitability & Growth : 3/10

Current vs industry vs history
ROE % -63.68
ROA % -57.15
ROC (Joel Greenblatt) % -388.38
3-Year Total EBITDA Growth Rate -58.70
N/A
3-Year EPS w/o NRI Growth Rate -33.00
N/A

» ATRA's 30-Y Financials

Financials (Next Earnings Date: 2019-05-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ATRA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2836
Compare TSE:4565 NAS:ENTA NAS:IOVA NAS:ICPT TSE:4592 SZSE:002030 OSTO:VITR NAS:RGEN NAS:PRTA NAS:IMGN XKRX:005250 XSWX:SFZN NAS:MDGL NAS:INVA NAS:XNCR NAS:TBPH NAS:ARNA NAS:INSM SZSE:002275 BOM:539268
Traded in other countries AT2.Germany
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening diseases. The company achieves this through two groups of product candidates, such as allogenic or third-party derived antigen-specific T-cells and molecularly targeted biologics.

Ratios

Current vs industry vs history
PB Ratio 4.31
EV-to-EBIT -4.90
EV-to-EBITDA -4.98
Current Ratio 8.04
Quick Ratio 8.04

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -15.50

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.31
Earnings Yield (Joel Greenblatt) % -20.41

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N